✦ LIBER ✦

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

✍ Scribed by Terpos, E; Kastritis, E; Roussou, M; Heath, D; Christoulas, D; Anagnostopoulos, N; Eleftherakis-Papaiakovou, E; Tsionos, K; Croucher, P; Dimopoulos, M A

Book ID: 109886654
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 40 KB
Volume: 22
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2008.288

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The combination of bortezomib, melphalan

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

✍ Heath, D; Terpos, E; Kastritis, E; Roussou, M; Christoulas, D; Anagnostopoulos, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 177 KB

The combination of intermediate doses of

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

✍ Terpos, E; Mihou, D; Szydlo, R; Tsimirika, K; Karkantaris, C; Politou, M; Voskar 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB

Bortezomib in combination with epirubici

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

✍ Shuqing Lü; Jianmin Wang; Xiaoqian Xu; Xiong Ni; Chongmei Huang; Huiying Qiu; Xi 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 158 KB